I
schaemia modified albumin (IMA) is a recently developed biomarker of transient myocardial ischaemia. 1 Circulating IMA is increased in patients with myocardial ischaemia, after percutaneous coronary intervention, 2 3 or in acute coronary syndromes. 4 The test has recently been licensed by the US Food and Drug Administration for diagnostic use in suspected myocardial ischaemia. IMA is serum albumin in which the N-terminus has been chemically modified. The diagnostic albumin Co 2+ binding (ACB) test is based for IMA on the observation that the affinity of serum albumin for Co 2+ is reduced after N-terminus modifications. It has been proposed that reactive oxygen species (ROS) such as superoxide ( N O 2 2 ) and hydroxyl ( N OH) radicals generated during myocardial ischaemia-reperfusion modify the N-terminus of serum albumin resulting in IMA formation but, so far, direct evidence to support this is scarce. We hypothesised that ROS generation causes the formation of IMA. Our objective was to model the formation of IMA in vitro by using chemically generated ROS and the N OH radical scavenger mercaptopropionylglycine (MPG).
MATERIALS AND METHODS
All reagents were obtained from Sigma-Aldrich (Poole, Dorset, UK) and normal human serum from the North London Transfusion Service (London, UK). Serum pH was 7.35-7.45 at 37˚C and was unaltered by any of the reactants during the 15 minute experimental time course. Five millilitre serum aliquots (eight replicate experiments per group) were randomly selected for the following incubations for 15 minutes at 37˚C. Group is not sequestered at the N-terminus of albumin, leaving more free Co 2+ to react. The total interassay coefficient of variation was 4.9-7.5% at 72.54-140.16 U/ml for quality control material. For human serum pools, the total coefficient of variation was 5.3-8.8% at 95.07-97.35 U/ml.
The percentage change in IMA in each group was calculated as follows: (IMA concentration at each time point 2 baseline IMA concentrations)/baseline IMA concentration 6 100. Results are expressed as mean (SE) of eight replicate experiments. IMA concentrations for each treatment were time matched by repeated measures analysis of variance with Bonferroni post hoc comparisons by SPSS 11.0 statistical software (SPSS Inc, Chicago, Illinois, USA). Results were considered significant when p , 0.05. (K a = 1.5 6 10 16 l/mol) is many orders of magnitude higher than that for Co 2+ (K a = 6.5 6 10 3 l/mol). However, in these experiments we observed no appreciable interference of Cu 2+ .
RESULTS

DISCUSSION
In vivo modifications of the albumin N-terminus are proposed to be related to the ROS production during myocardial ischaemia-reperfusion. For example, an increase in IMA was observed in patients minutes after transient occlusion and reperfusion during coronary angioplasty. 2 3 The present in vitro investigation shows for the first time that IMA formation is directly related to ROS generation and provides novel information on the nature of the species contributing to IMA formation, namely N OH. Previous studies in vitro have shown that the exposure of albumin to N OH generated by copper (at similar concentrations to those used in our experimental series) and ascorbate resulted in modification of albumin in a site specific manner, rather than generalised degradation. 5 ROS generation in vitro caused structural changes in a synthetic N-terminus tetrapeptide, an octapeptide, and human albumin with loss of Co 2+ binding capacity. 6 Our data are in accordance with these findings, since we show here that N OH generation caused a rise of IMA concentrations. Moreover, the role of 2 has low chemical reactivity with albumin in vitro. It has been suggested that N O 2 2 per se is not deleterious but serves as a source of highly reactive secondary species such as N OH, which are responsible for biological damage. These data support the hypothesis that ROS, and specifically in our hands N OH, may chemically modify human serum albumin, resulting in IMA formation. This appears to be a plausible mechanism underlying this new diagnostic test. To improve the clinical utility of IMA a clear understanding of the mechanism of the reaction relevant to in vivo ischaemiareperfusion is essential. Clearly, further in vivo studies supported by data from clinical trials are required to confirm the novel mechanism we have identified in these in vitro studies. Moreover, it will be important to elucidate the anatomical sites of IMA formation and its value in the diagnosis of disease states associated with oxidative stress, including myocardial ischaemia. 
